| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.77▼ | 0.77▲ | 0.77▼ | 0.80▼ | 0.79▼ |
| MA10 | 0.77▼ | 0.77▼ | 0.76▲ | 0.88▼ | 0.66▲ |
| MA20 | 0.77▼ | 0.76▲ | 0.79▼ | 0.77▼ | 0.67▲ |
| MA50 | 0.76▲ | 0.82▼ | 0.88▼ | 0.61▲ | 0.98▼ |
| MA100 | 0.81▼ | 0.88▼ | 0.81▼ | 0.67▲ | 1.09▼ |
| MA200 | 0.88▼ | 0.79▼ | 0.72▲ | 0.94▼ | 1.22▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | 0.006▲ | 0.005▲ | -0.017▼ | 0.057▲ |
| RSI | 48.907▼ | 45.168▼ | 42.313▼ | 50.706▲ | 49.444▼ |
| STOCH | 62.865 | 44.052 | 58.119 | 35.549 | 65.915 |
| WILL %R | -74.691 | -51.042 | -40.102 | -69.231 | -43.711 |
| CCI | -21.392 | 22.141 | 37.502 | -46.788 | 74.799 |
|
Wednesday, November 19, 2025 08:37 AM
Femasys Inc. company and executive profile by Barron's. View the latest FEMY company infomation and executive bios.
|
|
Friday, November 14, 2025 01:11 PM
FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval –– $12 Million Financing Strengthens ...
|
|
Monday, November 10, 2025 06:00 AM
Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company’s presence in key European Markets -- ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 19/11/25 | 0.72 | 0.81 | 0.715 | 0.759 | 1,603,500 |
| 18/11/25 | 0.78 | 0.80 | 0.702 | 0.72 | 2,607,147 |
| 17/11/25 | 0.86 | 0.88 | 0.783 | 0.7963 | 2,477,838 |
| 14/11/25 | 0.75 | 0.95 | 0.75 | 0.8975 | 3,441,094 |
| 13/11/25 | 0.9143 | 0.957 | 0.8111 | 0.8266 | 3,807,504 |
| 12/11/25 | 0.975 | 1.04 | 0.94 | 0.9623 | 4,293,584 |
| 11/11/25 | 0.99 | 1.11 | 0.93 | 0.941 | 5,982,000 |
| 10/11/25 | 0.91 | 1.11 | 0.82 | 1.04 | 12,877,645 |
| 07/11/25 | 0.78 | 1.05 | 0.78 | 1.04 | 13,754,093 |
| 06/11/25 | 0.85 | 0.899 | 0.756 | 0.781 | 8,525,000 |
|
|
||||
|
|
||||
|
|